Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective

Overview

Journal Nutrients

Date 2020 Jun 6

PMID 32498383

Citations 17

Authors

Antonella Orlando

Valeria Tutino

Maria Notarnicola

Giuseppe Riezzo

Michele Linsalata

Caterina Clemente

Laura Prospero

Manuela Martulli

Benedetta DAttoma

Valentina De Nunzio

Francesco Russo

Affiliations

Soon will be listed here.

Abstract

Given the link between the minimal inflammation underlying irritable bowel syndrome (IBS) and dietary treatments, considerable attention has focused on diets low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs). In this context, inflammatory patterns and lipidomic investigations may shed light on the pathophysiological mechanisms whereby a low-FODMAP diet (LFD) improves the IBS diarrhoea (IBS-D) variant. Thus, we investigated whether a long-term LFD induced changes in symptom profiles, anthropometric characteristics, inflammatory markers (C-reactive protein, cyclooxygenase-2, and prostaglandin E2) and erythrocyte-membrane fatty acid (FA) composition in IBS-D patients. Twenty IBS-D patients underwent a 90 day personalised LFD programme, and were regularly evaluated at scheduled visits. At the diet's end, both IBS symptoms and anthropometric parameters were significantly improved. A significant decrease in prostaglandin E2 also accompanied these reductions. As for FAs, the putative inflammatory indicators, arachidonic acid (AA) levels and the AA/eicosapentaenoic acid ratio were significantly decreased. In conclusion, IBS-D patients following a controlled long-term LFD experienced improved symptom profiles and decreased inflammatory markers linked to FAs. Lipidomic data may be insightful for unravelling the molecular mechanisms associated with IBS-D pathophysiology.

Citing Articles

StepFit-18K: Improving Irritable Bowel Syndrome (IBS) Symptoms with a Simple, Structured Walking Intervention.

Franco I, Bianco A, Prospero L, Riezzo G, Bonfiglio C, Bagnato C J Clin Med. 2024; 13(22).

PMID: 39597828 PMC: 11594471. DOI: 10.3390/jcm13226684.

Relationship between Markers of Gut Barrier Function and Erythrocyte Membrane PUFAs in Diarrhea-Predominant IBS Patients Undergoing a Low-FODMAP Diet.

Linsalata M, Ignazzi A, DAttoma B, Riezzo G, Mallardi D, Orlando A Nutrients. 2024; 16(16).

PMID: 39203842 PMC: 11357486. DOI: 10.3390/nu16162706.

Effect of a 12-Week Walking Program Monitored by Global Physical Capacity Score (GPCS) on Circulating Cell-Free mtDNA and DNase Activity in Patients with Irritable Bowel Syndrome.

Chimienti G, Russo F, Bianco A, Maqoud F, De Virgilio C, Galeano G Int J Mol Sci. 2024; 25(8).

PMID: 38673878 PMC: 11050617. DOI: 10.3390/ijms25084293.

Diet and Lifestyle Modifications for Fibromyalgia.

Metyas C, Aung T, Cheung J, Joseph M, Ballester A, Metyas S Curr Rheumatol Rev. 2024; 20(4):405-413.

PMID: 38279728 PMC: 11107431. DOI: 10.2174/0115733971274700231226075717.

FODMAPs-Unknowns for Consumers: First Survey in Serbia.

Torbica A, Vujasinovic V, Radosavljevic M, Radivojevic G, Milovanovic I Nutrients. 2023; 15(21).

PMID: 37960346 PMC: 10648408. DOI: 10.3390/nu15214693.

References

Notarnicola M, Caruso M, Tutino V, Bonfiglio C, Cozzolongo R, Giannuzzi V . Significant decrease of saturation index in erythrocytes membrane from subjects with non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2017; 16(1):160. PMC: 5568099. DOI: 10.1186/s12944-017-0552-0. View

Tuck C, Reed D, Muir J, Vanner S . Implementation of the low FODMAP diet in functional gastrointestinal symptoms: A real-world experience. Neurogastroenterol Motil. 2019; 32(1):e13730. DOI: 10.1111/nmo.13730. View

Notarnicola M, Caruso M, Tutino V, De Nunzio V, Gigante I, De Leonardis G . Nutrition and lipidomic profile in colorectal cancers. Acta Biomed. 2018; 89(9-S):87-96. PMC: 6502197. DOI: 10.23750/abm.v89i9-S.7955. View

Kyle U, Bosaeus I, De Lorenzo A, Deurenberg P, Elia M, Gomez J . Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. 2004; 23(6):1430-53. DOI: 10.1016/j.clnu.2004.09.012. View

Blake M, Raker J, Whelan K . Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016; 44(7):693-703. DOI: 10.1111/apt.13746. View

Chey W, Kurlander J, Eswaran S . Irritable bowel syndrome: a clinical review. JAMA. 2015; 313(9):949-58. DOI: 10.1001/jama.2015.0954. View

Guerreiro M, Santos Z, Carolino E, Correa J, Cravo M, Augusto F . Effectiveness of Two Dietary Approaches on the Quality of Life and Gastrointestinal Symptoms of Individuals with Irritable Bowel Syndrome. J Clin Med. 2020; 9(1). PMC: 7019629. DOI: 10.3390/jcm9010125. View

Akiho H, Ihara E, Nakamura K . Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2011; 1(3):97-105. PMC: 3097950. DOI: 10.4291/wjgp.v1.i3.97. View

Coviello G, Tutino V, Notarnicola M, Caruso M . Erythrocyte membrane fatty acids profile in colorectal cancer patients: a preliminary study. Anticancer Res. 2014; 34(9):4775-9. View

10.

Verdu E, Armstrong D, Murray J . Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. Am J Gastroenterol. 2009; 104(6):1587-94. PMC: 3480312. DOI: 10.1038/ajg.2009.188. View

11.

Varney J, Barrett J, Scarlata K, Catsos P, Gibson P, Muir J . FODMAPs: food composition, defining cutoff values and international application. J Gastroenterol Hepatol. 2017; 32 Suppl 1:53-61. DOI: 10.1111/jgh.13698. View

12.

Chatgilialoglu C, Ferreri C, Lykakis I, Wardman P . Trans-fatty acids and radical stress: what are the real culprits?. Bioorg Med Chem. 2006; 14(18):6144-8. DOI: 10.1016/j.bmc.2006.05.052. View

13.

Schmulson M, Drossman D . What Is New in Rome IV. J Neurogastroenterol Motil. 2017; 23(2):151-163. PMC: 5383110. DOI: 10.5056/jnm16214. View

14.

Bai T, Xia J, Jiang Y, Cao H, Zhao Y, Zhang L . Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey. J Gastroenterol Hepatol. 2016; 32(5):1018-1025. DOI: 10.1111/jgh.13642. View

15.

Zugasti Murillo A, Arevalo F, Jauregui E . Diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) in the treatment of irritable bowel syndrome: indications and design. Endocrinol Nutr. 2016; 63(3):132-8. DOI: 10.1016/j.endonu.2015.10.009. View

16.

Clevers E, Tran M, Van Oudenhove L, Storsrud S, Bohn L, Tornblom H . Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. Nutrition. 2020; 73:110719. DOI: 10.1016/j.nut.2020.110719. View

17.

Breil C, Abert Vian M, Zemb T, Kunz W, Chemat F . "Bligh and Dyer" and Folch Methods for Solid-Liquid-Liquid Extraction of Lipids from Microorganisms. Comprehension of Solvatation Mechanisms and towards Substitution with Alternative Solvents. Int J Mol Sci. 2017; 18(4). PMC: 5412294. DOI: 10.3390/ijms18040708. View

18.

Chua C, Huang S, Cheng C, Bai C, Hsu C, Chiu H . Fatty acid components in Asian female patients with irritable bowel syndrome. Medicine (Baltimore). 2017; 96(49):e9094. PMC: 5728949. DOI: 10.1097/MD.0000000000009094. View

19.

Maagaard L, Ankersen D, Vegh Z, Burisch J, Jensen L, Pedersen N . Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J Gastroenterol. 2016; 22(15):4009-19. PMC: 4823251. DOI: 10.3748/wjg.v22.i15.4009. View

20.

Calder P . Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res. 2008; 52(8):885-97. DOI: 10.1002/mnfr.200700289. View